News

Catheter Ablation vs. Antiarrhythmic Drug Treatment of Persistent Atrial Fibrillation: A Multicenter, Randomized, Controlled Trial (SARA Study)

25.10.20131795

Is radiofrequency catheter ablation (RFCA) more effective than antiarrhythmic drug therapy (AADT) for preventing persistent atrial fibrillation (AF)?

6-Minute Walk Time Predicts TAVI Outcome

24.10.20131993

Among patients with chronic obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis, worse exercise capacity at baseline was associated with poorer outcomes, researchers found.

Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients

23.10.20131874

Among nontraditional cardiovascular risk factors, recent influenzalike infection is associated with fatal and nonfatal atherothrombotic events.

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial

22.10.20131863

Рatients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients.

Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis

21.10.20131730

The clinical armamentarium for anticoagulation has expanded substantially since the recent approval of dabigatran, rivaroxaban and apixaban for the prevention of stroke in atrial fibrillation.

UEFA Cup in the Hands of GUARANT International

20.10.20132150

The most important sports event of this summer was undoubtedly the 2013 UEFA Super Cup, which on the 30th of August had been hosted at Prague‘s Eden stadium.

Are Guidelines Followed Less When Treating Secondary Diagnosis of HF?

18.10.20131712

The quality of care for hospitalized heart failure (HF) patients could be dramatically improved with one change — extending the same standard of care to patients with HF as a secondary diagnosis that is currently recommended for patients with HF as a primary diagnosis, according to a study published in the Journal of the American College of Cardiology.